🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Haydar Frangoul takes the stage in the ASCO/AACR Joint Session: "Established Gene Therapy Options in the Clinic" 🧬 🔬 Exploring real-world gene therapy: successes, challenges & equitable access. #GeneTherapy #ASCOAACR #PrecisionMedicine #ASCO2025

SCRI patient, Jimi, shares his first-hand experience with sickle cell disease in a powerful ASCO/AACR Joint Session. #GeneTherapy #ASCOAACR #SCD #PrecisionMedicine #ASCO25

At #ASCO25, Dr. Erika Hamilton, MD presented Phase 3 VERITAC-2 results: 🧬 Vedegestrant (first PROTAC ER degrader) showed: ✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC) ✅ Favorable safety (<5% AEs led to dose changes) ⏳ OS data maturing A promising new option!

To all the fighters, heroes, mothers, grandmothers, friends, sons, coworkers, golf partners, sisters, bakers, neighbors and many more, happy National Cancer Survivors Day! Today, and every day we celebrate you. #NationalCancerSurvivorsDay scri.com/patients/

Meet the experts from Sarah Cannon Docs at the 2025 ASCO Annual Meeting! Visit booth #27022 to connect with leaders from across our organization and discover the latest in oncology research. uberflip.scri.com/i/1535506-meet…?

At #ASCO25, Dr. Naqash explores the promise & challenges of bispecific T-cell engagers (BiTEs) in lung cancer & beyond: ✅ Tarlatamab earns FDA nod for SCLC ⚠️ CRS & ICANS toxicity management is key 🎯 DLL3 & other targets may expand BiTE reach #Immunotherapy #LungCancer

Honoring a legacy in oncology! Dr. @Howard A. Burris III now has a Conquer Cancer Young Investigator Award in his name, recognizing his impact on cancer research. Congrats to inaugural recipient Dr. Allison Taylor! 🔗 scri.com/leadership/?co… #Oncology #CancerResearch #ASCO

Dr. Melissa Johnson tackled how community oncology can deliver cutting-edge lung cancer therapies: 🔹 Not all bispecifics need inpatient care 🔹 Tarlatamab = outpatient-friendly 🔹 Innovative care models = better access #LungCancer #Immunotherapy #SCRI #ASCO25

Live from #ASCO25, Dr. David R. Spigel, MD, FASCO breaks down AIM-HIGH findings on a 14-gene assay guiding chemo decisions in early-stage #NSCLC, with a nearly 80% reduction in recurrence or death for high-risk patients. Watch his interview in OncLive.com here: onclive.com/view/dr-spigel…

We look forward to seeing more of you on day four of the #ASCO25 Annual Meeting. Stop by both #27022 to meet experts from across the network, from 9:45am-2:00pm. #CancerResearch uberflip.scri.com/i/1535506-meet…

🚨 LIVE from #ASCO25 🚨 Dr. Erika Hamilton, MD presents first-in-human data on Emi-Le (B7-H4 ADC) in solid tumors. 🔹 ORR: 31% in B7-H4 high 🔹 ORR: 44% w/ ≤4 prior lines 🔹 ACC-I: 55.6% ORR Promising activity + tolerability in mBC, OC, EC & ACC-I. #SCRI #ADC #Oncology

📷 from #ASCO2025 where Sarah Cannon Docs, The US Oncology Network and Ontada are presenting a combined 170 abstracts on their latest research and innovations — showcasing their commitment to always advancing cancer research and care. Together, #CancerDoesntStandAChance.

Come meet SCRI expert, Erika Hamilton, MD at #ASCO25 booth 27022, now!

New data from the AIM-HIGH trial presented by Dr. David R. Spigel, MD, FASCO at #ASCO25 shows a 78% relative reduction in recurrence or death with adjuvant chemo for high-risk early-stage #NSCLC patients, identified via a 14-gene molecular assay. Watch interview here: ascopost.com/videos/2025-as…

Happening now at #ASCO25! Dr. Naqash serves as chair during the Oral Abstract Session: Lung Cancer-Non- Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session.

Dr. Cloven shares her #ASCO25 poster on “Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.”

Dr. Vivek Subbiah, MD shared final ARROW trial results on a developmental therapy for RET fusion-positive solid tumors at #ASCO25 yesterday. Thank you Dr. Subbiah for an insightful session on efficacy and safety!

Dr. Meredith McKean delivers her oral presentation on Novel Targets in #Melanoma Treatment at #ASCO2025

Tomorrow, SCRI's Dr. Yardley will join Industry Dive in a State of Oncology Research Virtual Event. Join her June 5, 1PM ET. dive.pub/43zAmrB #CancerNews #OncologyResearch #SCRI #BreastCancerNews

Thank you, #ASCO25! We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration. Here’s to advancing therapies for patients —together. Until next year! #SCRI #CancerResearch #OncologyLeadership #ThankYouASCO